Four Dental Experts Join Oragenics, Inc.' International Scientific Advisory Board

ALACHUA, Fla., July 13 /PRNewswire-FirstCall/ -- Oragenics, Inc. announces that Dr. Raman Bedi, Chairman of Oragenics' International Scientific Advisory Board, has enlisted four global dental experts to join Oragenics' International Scientific Advisory Board: Dr. Ayyaz Khan of Pakistan, Dr. Brian Mouatt of the United Kingdom, Dr. Hari Parkash of India and Dr. Eli Schwarz of Australia. Dr. Bedi is the former Chief Dental Officer of England, recipient of the Foundation chair in Transcultural Health at University College London, a recipient of the first annual Asian Power 100 list, as well as numerous other accomplishments in the area of oral health worldwide. Dr. Khan is the most senior dental advisor to the Health Ministry in Pakistan. He is currently the Head of the Department of Oral Health Sciences at Shaikh Zayed Medical Center in Lahore, Pakistan and is the National Coordinator for Oral Health for a Joint WHO/Government of Pakistan Program. Dr. Mouatt served as the 5th Chief Dental Officer for England and previously served as the Chief Dental Officer for Zambia. He is the past chair of the International Dental Federation (FDI) World Dental Development Health Promotion Committee and the current President of the Commonwealth Dental Association. Dr. Parkash is one of the most senior dental advisors to the federal government of India and is currently the Director for ITS Center Dental Studies and Research, Ghaziabad, (U.P.) India. In addition, Dr. Parkash has served as Project Director, National Oral Health Care Program of India, Ministry of Health and Family Welfare, Past President, Int. Coll. of Dent. (India & Sri Lanka Sect.). Dr. Schwarz served as the Chief Dental Officer of Denmark, and served in the National Board of Health, Copenhagen Denmark. Dr. Schwarz's distinguished career includes being conferred the Royal Order, Knight of the Order of Dannebrog, by Her Majesty Queen Margrethe II of Denmark. Currently, he is Professor and Dean at the Faculty of Dentistry at the University of Sydney, Australia.

"To have Dr. Bedi agree to Chair our International Scientific Advisory Board and to have four dental experts of such prominence as Drs. Khan, Mouatt, Parkash, and Schwarz consent to serve on the Board is quite an honor for Oragenics," said "Dr. Zahradnik, Oragenics' Chief Executive Officer. "We are excited about working with these five past-Chief Dental Officers on a global strategy for advancing our technologies through clinical trials, partnering, and commercialization.

"Oragenics is a global company with products that will dramatically influence the health of everyone. We have reflected this global dimension with our selection of international advisors. It is a privilege to lead such internationally renowned scientists and dental leaders. Interest in Oragenics' potential has arisen from both investors and scientists across four continents. Within this calendar year we should have demonstrated the clinical effectiveness of a dental product which will transform the oral hygiene industry," said Raman Bedi.

The advisory group has begun identifying strategic alliances in Asia and Middle East. These efforts by the International Scientific Advisory Board are expected to result in a global strategy for conducting clinical trials for SMaRT Replacement Therapy(TM). Oragenics currently plans to initiate multi- center clinical trials outside the United States in early to mid-2007, once regulatory approval is received.

On an unrelated matter, a study is currently being conducted for Oragenics' cosmetic mouth rinse product, Probiora3(TM), to substantiate the claim that it helps maintain a healthy beneficial bacteria in the human mouth. The first subjects have been enrolled and upon completion of the study in September, Oragenics will finalize the selection of partners for commercialization of this unique oral probiotic product.

About Oragenics

Oragenics, Inc. is a biopharmaceutical company with a pipeline of proprietary technologies. The Company has a number of products in discovery, preclinical and clinical development, with a concentration in two main therapeutic areas: infectious disease and oncology. Oragenics' core pipeline includes products for use in the treatment of dental and periodontal infectious diseases, systemic bacterial infections and obesity. In the discovery stage are three platform technologies for identifying biomarkers of infection, cancer and autoimmune diseases and for the solid state synthesis of bioactive peptides including small molecule antibiotics.

Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995. This release includes forward-looking statements that reflect Oragenics' current views with respect to future events and financial performance. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project" and similar expressions that do not relate solely to historical matters identify forward- looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to those set forth in our most recently filed annual report on Form 10-KSB and quarterly report on Form 10-QSB and other factors detailed from time to time in filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements.

For more information about Oragenics, please consult the company's website at .

Oragenics, Inc.

CONTACT: Robert T. Zahradnik, Ph.D., Oragenics, Inc., +1-386-418-4018,ext. 222

Back to news